Efficacy of Metoclopramide in Poor Ovarian Response IVF Patients

Barzilai Medical Center

Status: Enrolling

Conditions: Poor Responders in IVF

Treatments: Drug: Metoclopramide; Drug: Placebo Oral Tablet

Study type: Interventional

Funder types: Other

Identifiers

NCT03560583

BRZ 0046-17 CTIL

Details and patient eligibility

About

Poor ovarian response population of ART are considered the biggest challenge for providers. Hitherto, no one protocol has been proven to be effect in this subgroup of IVF patients.

Metoclopramide belongs to the antiemetic group, used for motion sickness and during early gestation for hyperemesis gravidarum.

The mechanism of action is antagonisim to dopamine receptors. We hypothesize than by blocking dopamine receptors and decreasing the dopaminergic tone there is a possibility to increase the sensitivity of ovarian response to gonadotropins during controlled ovarian stimulation and result in increased oocyte retrival.

Enrollment: 60 estimated patients

Sex: Female

Ages: 18 to 54 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Poor response according to "Bologna criteria"

Exclusion criteria

• Allergy to metoclopramide
• Prolactinemia
• Women treated with dopamine agonists

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

60 participants in 2 patient groups, including a placebo group

Metoclopramide 10 mg BID

Experimental group

Treatment:

Drug: Metoclopramide

Placebo 10 mg BID

Placebo Comparator group

Treatment:

Drug: Placebo Oral Tablet